Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adial Pharmaceuticals ( (ADIL) ) has provided an announcement.
On August 1, 2025, Adial Pharmaceuticals held its Annual Meeting of Stockholders, where significant approvals were made, including the amendment to increase the number of shares under the 2017 Equity Incentive Plan from 2,000,000 to 5,000,000. Additionally, the stockholders approved an amendment to the company’s Certificate of Incorporation to double the authorized shares of common stock from 50,000,000 to 100,000,000, reflecting a strategic move to enhance financial flexibility and support future growth initiatives.
The most recent analyst rating on (ADIL) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.
Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for addiction and related disorders. The company is known for its work on therapies targeting alcohol use disorder and other substance abuse conditions.
Average Trading Volume: 9,148,065
Technical Sentiment Signal: Sell
Current Market Cap: $6.88M
Find detailed analytics on ADIL stock on TipRanks’ Stock Analysis page.